Related Experiment Video
Updated: Aug 6, 2026

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders
Published on: September 4, 2011
Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity
C L Bevan1, B B Brown, H R Davies
1University Department of Paediatrics, University of Cambridge, UK.
Abstract:
Partial androgen insensitivity syndrome (PAIS) is caused by defects in the androgen receptor gene and presents with a wide range of undervirilization phenotypes. We studied the consequences of six androgen receptor ligand-binding domain mutations on receptor function in transfected cells. The mutations, Met742Ile, Met780Ile, Gln798Glu, Arg840Cys, Arg855His and Ile869Met, were identified in PAIS patients with phenotypes representing the full spectrum seen in this condition. In all cases the androgen receptor was found to be defective, suggesting that the mutation is the cause of the clinical phenotype. The Gln798Glu mutation is exceptional in that it did not cause an androgen-binding defect in our system, although the mutant receptor was defective in transactivation assays. This mutation may affect an aspect of binding not tested, or may be part of a functional subdomain of the ligand-binding domain involved in transactivation. Overall we found milder mutations to be associated with milder clinical phenotypes. There is also clear evidence that phenotype is not solely dependent on androgen receptor function. Some of the mutant receptors were able to respond to high doses of androgen in vitro, suggesting that patients carrying these mutations may be the best candidates for androgen therapy. One such mutation is Ile869Met. A patient carrying this mutation has virilized spontaneously at puberty, so in vivo evidence agrees with the experimental result. Thus a more complete understanding of the functional consequences of androgen receptor mutations may provide a more rational basis for gender assignment in PAIS.
Insights
Partial androgen insensitivity syndrome (PAIS) results from androgen receptor gene defects. Studying mutations reveals varying receptor functions, guiding potential androgen therapy and gender assignment for PAIS patients.
Area of Science:
- Genetics
- Endocrinology
- Molecular Biology
Background:
- Partial androgen insensitivity syndrome (PAIS) is a genetic disorder characterized by undervirilization due to androgen receptor (AR) gene defects.
- PAIS presents with a broad spectrum of clinical phenotypes, making diagnosis and management challenging.
Purpose of the Study:
- To investigate the functional consequences of six specific AR ligand-binding domain mutations found in PAIS patients.
- To correlate AR mutation function with clinical phenotypes and explore potential therapeutic strategies.
Main Methods:
- Transfected cells were used to study the function of six AR mutations (Met742Ile, Met780Ile, Gln798Glu, Arg840Cys, Arg855His, Ile869Met).
- Receptor binding and transactivation assays were performed to assess the impact of each mutation on AR activity.
Main Results:
- All studied AR mutations resulted in defective receptor function, correlating with the clinical presentation in PAIS patients.
- The Gln798Glu mutation impaired transactivation but not androgen binding, suggesting complex functional effects.
- Milder AR mutations were associated with less severe clinical phenotypes, and some mutants responded to high androgen doses in vitro.
Conclusions:
- AR gene mutations are the cause of PAIS, with varying functional impacts.
- Understanding AR mutation consequences can inform androgen therapy selection and improve gender assignment decisions for PAIS patients.
- Phenotype is influenced by AR function, but other factors also play a role in PAIS presentation.
More Related Videos
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019